Form 483

Mylan Laboratories Limited Form 483, 2022-09-23

FDA issued a Form 483 to Mylan Laboratories Limited on 2022-09-23 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

Mylan Laboratories Limited · Hosur, India · Issued September 23, 2022

Overview

  • 6 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

23 Sep 2022
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Thomas J Arista

23 Sep 2022
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Thomas J Arista

23 Sep 2022
21 CFR 211.22(c)

Approve or reject procedures or specs

Cited by Thomas J Arista

23 Sep 2022
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Thomas J Arista

23 Sep 2022
21 CFR 211.68(a)

Calibration/Inspection/Checking not done

Cited by Thomas J Arista

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations2x
21 CFR 211.22(c)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(6)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere